InvestSMART

Resonance Health Limited (ASX: RHT) - Announcements

Current share price for RHT : $0.058 0.002 (3.33%)+

ASX company news and announcements for Resonance Health Limited (RHT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Resonance Health Limited (RHT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Resonance Health Limited (RHT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Resonance Health Limited (RHT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$28 Half Year Report and Accounts 28 Feb 2013 6:19PM $0.016 $0.058 risen by 262.50%
$28 US Insurance Company-FerriScan eligible for reimbursement 11 Feb 2013 2:34PM $0.017 $0.058 risen by 241.18%
$28 Appendix 4C - quarterly 31 Jan 2013 7:36PM $0.017 $0.058 risen by 241.18%
$28 FerriScan FDA cleared as companion diagnostic device 24 Jan 2013 5:41PM $0.017 $0.058 risen by 241.18%
$28 Fibrosis Update 21 Dec 2012 6:12PM $0.017 $0.058 risen by 241.18%
$28 FerriScan gains ground with US Insurance Payers 7 Nov 2012 1:29PM $0.017 $0.058 risen by 241.18%
$28 Appendix 4C - quarterly 31 Oct 2012 9:53AM $0.020 $0.058 risen by 190%
$28 FerriScan contracted for two new Clinical Trials 23 Oct 2012 3:11PM $0.016 $0.058 risen by 262.50%
$28 FDA requests a broader Indication for Use for Ferriscan 18 Oct 2012 1:18PM $0.014 $0.058 risen by 314.29%
$28 Preliminary Final Report 31 Aug 2012 3:53PM $0.009 $0.058 risen by 544.44%
$28 Appendix 4C - quarterly 30 Apr 2012 6:08PM n/a $0.058 n/a
$28 Update on HepaFat Scan and Liver Fibrosis Test 5 Apr 2012 12:38PM $0.011 $0.058 risen by 427.27%
$28 Half Yearly Report and Accounts 29 Feb 2012 1:33PM $0.014 $0.058 risen by 314.29%
$28 Appendix 4C - quarterly 31 Jan 2012 3:40PM $0.016 $0.058 risen by 262.50%
$28 Patent Application Lodged for MRI Measurement of Fatty Liver 9 Dec 2011 2:17PM $0.015 $0.058 risen by 286.67%
$28 Resonance Health appoints Middle East distributor 5 Dec 2011 4:34PM $0.013 $0.058 risen by 346.15%
$28 Appendix 4C - quarterly 31 Oct 2011 2:48PM $0.016 $0.058 risen by 262.50%
$28 Preliminary Final Report 31 Aug 2011 2:49PM $0.015 $0.058 risen by 286.67%
$28 FDA clearance to market cardiac iron test in USA 3 Aug 2011 9:16AM $0.019 $0.058 risen by 205.26%
$28 Appendix 4C - monthly 29 Jul 2011 2:56PM $0.017 $0.058 risen by 241.18%
$28 RHT Develops Accurate Fatty Liver Diagnostic Test 23 May 2011 10:56AM $0.025 $0.058 risen by 132%
$28 Appendix 4C - quarterly 29 Apr 2011 3:42PM $0.023 $0.058 risen by 152.17%
$28 Expands Master Service Agreement with Novartis 10 Mar 2011 12:31PM $0.032 $0.058 risen by 81.25%
$28 Half Yearly Report and Accounts 25 Feb 2011 1:04PM $0.021 $0.058 risen by 176.19%
$28 RHT signs agreement with Pfizer 11 Feb 2011 3:18PM $0.039 $0.058 risen by 48.72%

426 - 450 of 531 results

Page 18 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.